Safety of suppressive therapy with levothyroxine: Effects on bone metabolism and cardiac function and morphology and potential benefits of the use of alendronate and β-blockers

Endocrinologist

Volumn 17, Issue 3, 2007, Pages 148-151

  Souza Rosário, Pedro Weslley ^a,c   Borges, Michelle Aparecida Ribeiro ^a   Vasconcelos, Flavio Jesus ^a   Alves, Maria Flávia Gatti ^a   Purisch, Saulo ^a   Padrao, Eduardo Lanza ^b   Rezende, Leonardo Lamego ^b   Barroso, Alvaro Luís ^b  

^a Endocrinology Service   (Brazil)

^b Nuclear Medicine Service   (Brazil)

^c Centro de Estudos e Pesquisa da Clinica de Endocrinologia e Metabologia CEPCEM   (Brazil)

Author keywords

Bone markers; Cardiac function; Suppressive therapy

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; LEVOTHYROXINE; OSTEOCALCIN; PARATHYROID HORMONE; PROPRANOLOL;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE MASS; HEART RATE; HOLTER MONITORING; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SUPRAVENTRICULAR TACHYCARDIA; THYROIDECTOMY;

EID: 34248996552     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000264938.53952.84     Document Type: Article

References (24)

1. Ringel MD, Ladenson PW. Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Relat Cancer. 2004;11:97-116.
2. Toft AD. Subclinical hyperthyroidism. N Engl J Med. 2001;345:512-516.
3. Fazio S, Palmieri EA, Lombardi G, et al. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59:31-50.
4. Quan ML, Pasieka JL, Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol. 2002;79:62-69; discussion 69-70.
5. Schneider R, Reiners C. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature. Exp Clin Endocrinol Diabetes. 2003;111:455-470.
6. Rossen HN, Moses AC, Garber J, et al. Randomized trial of pamidronate in patients with thyroid cancer: bone density in not reduced by suppressive doses of thyroxine but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab. 1998;83:2324-2330.
7. Mikosch P, Obermayer-Pietsch B, Jost R, et al. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment. Thyroid. 2003;13:347-356.
8. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem. 1999;45:1359-1368.
9. Sahn DJ, DeMaria NA, Kisslo J, et al. The Committee on M-mode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
10. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Coll Cardiol. 1986;57:450-458.
11. Schiller NB, Shah PM, Crawford M, et al. Recommendation for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358-367.
12. Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol. 1984;4:1222-1230.
13. Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurement in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab. 1991;72:1184-1188.
14. Wesche MF, Tiel V, Buul M, Lips P, et al. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab. 2001;86:998-1005.
15. Giannini S, Nobile M, Sartori L, et al. Bone density and mineral metabolism in thyroidectomized patients treated with long-term L-thyroxine. Clin Sci (Lond.). 1994;87:593-597.
16. Jodar E, Begona Lopez M, Garcia L, et al. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass. Osteoporos Int. 1998;8:311-316.
17. Jureka-Tuleja B, August R, Kukulska A, et al. Evaluation of bone density in women after thyroid cancer surgery and treatment with suppressive doses of L-thyroxine. Wiad Lek. 2001;54:378-382.
18. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 1999;84:2363-2368.
19. Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade. J Clin Endocrinol Metab. 1995;80:2222-2226.
20. Gullu S, Altuntas F, Dincer I, et al. Effects of TSH suppressive therapy on cardiac morphology and function: beneficial effects of the addition of beta-blockade on diastolic dysfunction. Eur J Endocrinol. 2004;150:655-661.
21. Biondi B, Fazio S, Palmieri EA, et al. Effects of chronic subclinical hyperthyroidism from levothyroxine on cardiac morphology and function. Cardiologia. 1999;44:443-449.
22. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1993;77:334-338.
23. Shapiro LE, Sievert R, Ong L, et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin- suppressive doses of L-thyroxine. J Clin Endocrinol Metab. 1997;82:2592-2595.
24. Biondi B, Fazio S, Carella C, et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1994;78:1028-1033.